MedTrace Logo

Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

NCT03298802 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2023-12-05

No results posted yet for this study

Summary

Postpartum prophylactic HCTZ administration for prevention and relapse of preeclampsia or gestational hypertension.

Conditions

  • Pre-Eclampsia
  • Gestational Hypertension
  • Superimposed Pre-Eclampsia
  • Hypertension, Pregnancy-Induced
  • Postpartum Pregnancy-Induced Hypertension
  • Postpartum Preeclampsia

Interventions

DRUG

Hydrochlorothiazide 50mg Tablet

Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.

DRUG

Placebo Tablet

Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • Benjamin Bush, M.D. · UTMB

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-21
Primary Completion
2024-08-30
Completion
2024-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03298802 on ClinicalTrials.gov